Clinical characteristics at disease onset and at last clinical review stratified by anti-cN-1A antibody status
| Clinical feature | Anti-cN-1A positive (%) | Anti-cN-1A negative (%) | OR (95% CI) | p Value |
|---|---|---|---|---|
| At disease onset | ||||
| Proximal upper limb weakness (n=252) | 7/84 (8.3) | 39/168 (23.2) | 0.30 (0.13 to 0.71) | 0.006* |
| Proximal lower limb weakness (n=253) | 65/85 (76.5) | 122/168 (72.6) | 1.23 (0.67 to 2.24) | 0.510 |
| Distal upper limb weakness (n=251) | 22/83 (26.5) | 40/168 (23.8) | 1.15 (0.63 to 2.11) | 0.641 |
| Distal lower limb weakness (n=250) | 7/83 (8.4) | 20/167 (12.0) | 0.68 (0.27 to 1.67) | 0.398 |
| Dysphagia (n=119) | 15/36 (41.7) | 23/83 (27.7) | 1.86 (0.82 to 4.22) | 0.136 |
| Axial involvement (n=102) | 0/30 (0.0) | 3/72 (4.2) | 1 | – |
| Symmetrical weakness (n=97) | 25/37 (67.6) | 32/60 (53.3) | 1.82 (0.78 to 4.29) | 0.169 |
| At last review | ||||
| Proximal lower limb weakness (n=137) | 35/40 (87.5) | 80/97 (82.5) | 1.49 (0.51 to 4.35) | 0.468 |
| Distal upper limb weakness (n=135) | 40/41 (97.6) | 89/94 (94.7) | 2.25 (0.25 to 19.86) | 0.466 |
| Distal lower limb weakness (n=125) | 23/43 (53.5) | 36/82 (43.9) | 1.47 (0.70 to 3.08) | 0.309 |
| Dysphagia (n=303) | 63/100 (63.0) | 113/203 (55.7) | 1.36 (0.83 to 2.22) | 0.224 |
| Facial weakness (n=90) | 18/33 (54.6) | 18/57 (31.6) | 2.60 (1.07 to 6.29) | 0.034† |
| Axial involvement (n=84) | 9/26 (34.6) | 10/58 (17.2) | 2.54 (0.88 to 7.31) | 0.084 |
| Clinical evidence of polyneuropathy (n=103) | 13/38 (34.2) | 31/65 (47.7) | 0.57 (0.25 to 1.31) | 0.184 |
Figures in brackets represent within antibody group percentages. n represents data available for analysis per variable (of a total of 311). p Value is derived from logistic regression. Data regarding certain variables (proximal upper limb weakness, facial weakness, symmetrical weakness and clinical evidence of polyneuropathy) were only available at either disease onset or at last review.
*Adjusted (for age at disease onset, gender and comorbidities) OR 0.29, 95% CI 0.12 to 0.68, p=0.005.
†Adjusted (for age at disease onset, gender and comorbidities) OR 3.03, 95% CI 1.20 to 7.67, p=0.019.
Anti-cN-1A, anticytosolic 5′-nucleotidase 1A.